ATLANTA--(BUSINESS WIRE)--Dec. 12, 2005--MGI PHARMA, INC. (Nasdaq:MOGN) and SuperGen, Inc. (Nasdaq:SUPG) today provided a summary of the Dacogen(TM) (decitabine) injection presentations made during the American Society of Hematology (ASH) 47th Annual Meeting and Exposition. Dacogen injection was the subject of five oral presentations and 10 poster presentations. Updated results from an alternative dosing study of Dacogen injection in patients with myelodysplastic syndromes (MDS) and initial data from a phase 2 trial of Dacogen injection in elderly acute myeloid leukemia (AML) patients were among the data presented. In addition, MGI PHARMA sponsored a Corporate Friday symposium titled Modulation of Methylation Status: Innovation in the Treatment of Hematological Malignancies, which was chaired by Dr. Jean-Pierre Issa of The University of Texas M.D. Anderson Cancer Center in Houston, TX.
